News

Statins reduce this buildup by reducing C-reactive protein, a measure of inflammation in the arteries. A related analysis at Boston’s Brigham and Women’s Hospital demonstrates that lowering C-reactive

The randomized, placebo controlled, double blind phase IIb study is designed to evaluate the effectiveness of CS-917 in lowering blood glucose levels in patients with type 2 diabetes.

In addition, Diatos has also received rights to sublicense OncoGel and to develop and commercialize second generation OncoGel products. Diatos and MacroMed, both privately held biopharmaceutical companies, will

The researchers demonstrated that ceftriaxone, a beta-lactam antibiotic, turns on a gene that encodes for the glutamate transporter GLT-1. As a result, more glutamate transporter protein is present

Epratuzumab is a versatile humanized monoclonal antibody targeting B-cell-mediated autoimmune diseases and non-Hodgkin’s Lymphoma. According to Cynthia Sullivan, president and CEO of Immunomedics, the company’s clinical plans for

Upon consummation of the transaction, Tarpan shareholders will own approximately 20% of the shares of Manhattan on a fully-diluted basis. Upon the close of the transaction, Manhattan Pharmaceuticals’

Zelapar (selegiline hydrochloride) is a late-stage candidate under review by the FDA as an oral tablet using the patented Zydis fast-dissolving technology and is being developed as an

The terms of the collaboration include sponsored research activities, product development milestones, and financial consideration associated with therapeutic and diagnostic products that result from the collaboration. Detailed financial

Sangamo will generate novel cell lines and vector systems for enhanced protein production as well as novel technology for rapid and robust creation of new production cell lines.